Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
20
datasets available to search
ShareScore release 0.9.0
Dataset results
20 results for “lipid lowering treatment”
Data from: Clinical characteristics and lipid lowering treatment of patients initiated on Proprotein convertase subtilisin/kexin type 9 inhibitors – a nationwide cohort study
Objectives: Given the novelty of proprotein convertase subtilisin–kexin type 9 inhibitors (PCSK9i), little is known regarding overall implementation or clinical characteristics among patients who initiate treatment. We aimed to assess the total number of patients initiated on PCSK9i along with a description of the clinical characteristics and lipid lowering treatment (LLT) of such patients. Setting: A register based descriptive cohort study of patients receiving a PCSK9i in the time period from 01-01-2016 to 31-03-2017 using a cross-linkage between three nationwide Danish registers. Information regarding PCSK9i prescriptions, patient demographics, concurrent pharmacotherapy, comorbidities, and previous coronary procedures was identified. Results: Overall, 137 patients initiated treatment with PCSK9i in the study period from 11 in the first quarter of 2016 to 40 in the first quarter of 2017. The majority had a history of ischemic heart disease (67.9%) with ischemic stroke and diabetes mellitus being present in 7.3% and 16.8% of patients, respectively. All patients initiated on PCSK9i had been previous prescribed statin treatment with Atorvastatin and Simvastatin being most frequently prescribed in 53% and 36% of patients, respectively. The majority of patients had received both statins and Ezetimibe (94.9%) and approximately half of these patients had also received bile acid sequestrant (45.3%). Clinical characteristics mainly differed in patients receiving triple LLT compared to patients not receiving triple LLT in the regards of heart failure. Conclusion: Patients treated with PCSK9i were rare, characterized by having ischemic heart disease and had received various and intensive conventional LLT prior to PCSK9i initiation in agreement with current international guidelines.
Atlantic Lipid Lowering Treatment Optimization Program
ClinicalTrials.gov study NCT06439654. IPD Sharing: NO. Countries: 1. Publications: 5.
Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia
ClinicalTrials.gov study NCT00263081. IPD Sharing: Not stated. Countries: 6. Publications: 1.
Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Endothelial Function
ClinicalTrials.gov study NCT01223625. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Clinical Study to Evaluate the Effect of Mobile Applications "My A:Care" and "Smart Coach" on the Lipid-lowering Treatment Adherence of Subjects With Dyslipidemia in Thailand
ClinicalTrials.gov study NCT05370703. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment
ClinicalTrials.gov study NCT01035320. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Plaque Composition in Patients With ST-Segment Elevation Myocardial Infarction (MI)
ClinicalTrials.gov study NCT01058915. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Adequacy of the Indication of Lipid Lowering Treatment in Primary Prevention
ClinicalTrials.gov study NCT01997671. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Clinical characteristics and lipid lowering treatment of patients initiated on Proprotein convertase subtilisin/kexin type 9 inhibitors – a nationwide cohort study
Open the record for dataset details and reuse information.
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
ClinicalTrials.gov study NCT00000542. IPD Sharing: Not stated. Countries: 0. Publications: 78.
Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion
ClinicalTrials.gov study NCT07002476. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis
ClinicalTrials.gov study NCT00433823. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Community Pharmacist-led Intervention to Improve Adherence to Lipid-lowering Treatment
ClinicalTrials.gov study NCT00493337. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment
ClinicalTrials.gov study NCT01245894. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Early Effects of Intensive Lipid Lowering Treatment With Ezetimibe/ Simvastatin (Vytorin®) Assessed by Virtual Histology-Intravascular Ultrasound (VH-IVUS) and Optical Coherence Tomography (OCT) on Pl
ClinicalTrials.gov study NCT01857843. IPD Sharing: Not stated. Countries: 1. Publications: 0.
INdians Followed for INtensive Lipid Lowering Treatment and Its safetY
ClinicalTrials.gov study NCT00664469. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima-media Thickness (CIMT)
ClinicalTrials.gov study NCT01203982. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting
ClinicalTrials.gov study NCT05362903. IPD Sharing: NO. Countries: 1. Publications: 0.
Intensive Lipid Lowering Treatment in Non-ST-elevation Acute Coronary Syndrome (NSTE-ACS) Patients
ClinicalTrials.gov study NCT01040936. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)
ClinicalTrials.gov study NCT00726856. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.